ZEN, MARGHERITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.252
EU - Europa 1.223
AS - Asia 736
SA - Sud America 12
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 8.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.251
IT - Italia 697
CN - Cina 376
SG - Singapore 289
DE - Germania 125
FI - Finlandia 119
GB - Regno Unito 72
SE - Svezia 63
FR - Francia 52
UA - Ucraina 26
IN - India 23
JP - Giappone 22
NL - Olanda 20
IE - Irlanda 16
HK - Hong Kong 11
ES - Italia 10
PE - Perù 10
EG - Egitto 7
RU - Federazione Russa 6
EU - Europa 4
NZ - Nuova Zelanda 4
CZ - Repubblica Ceca 3
GR - Grecia 3
IR - Iran 3
PL - Polonia 3
BD - Bangladesh 2
BR - Brasile 2
BY - Bielorussia 2
IL - Israele 2
RO - Romania 2
TH - Thailandia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BE - Belgio 1
CA - Canada 1
ID - Indonesia 1
KG - Kirghizistan 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
NG - Nigeria 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 8.241
Salva come PNG Salva come JPEG
Città #
Fairfield 1.156
Woodbridge 575
Chandler 520
Ashburn 514
Houston 493
Seattle 437
Ann Arbor 432
Cambridge 394
Wilmington 345
Singapore 220
Santa Clara 162
Boardman 145
Jacksonville 121
Princeton 101
San Diego 90
Milan 79
Medford 76
Padova 75
Beijing 71
Des Moines 66
Helsinki 60
Nanjing 56
Rome 38
New York 21
Dearborn 19
Roxbury 19
Hebei 17
Jinan 17
Dublin 16
Naples 14
London 13
Falls Church 12
Guangzhou 12
Jiaxing 12
Nanchang 12
Shenyang 12
Verona 12
Bologna 11
Genoa 11
Cagliari 10
Hong Kong 10
Mito 10
Redwood City 10
Arezzo 9
Tianjin 9
Tsukuba 9
Turin 9
Falkenstein 8
Norwalk 7
Ogden 7
Pisa 7
Trieste 7
Changsha 6
Kharkiv 6
Los Angeles 6
Shanghai 6
Chiclayo 5
Hefei 5
Kilburn 5
Lappeenranta 5
Las Vegas 5
Marostica 5
Zhengzhou 5
Allauch 4
Azzano Decimo 4
Como 4
Ferrara 4
Haikou 4
Hangzhou 4
Madrid 4
Oderzo 4
Palermo 4
Prescot 4
Rockville 4
San Floriano del Collio 4
Stockholm 4
Tappahannock 4
Trani 4
Trento 4
Venice 4
Vigonza 4
Acton 3
Amsterdam 3
Bari 3
Brescia 3
Cairo 3
Cornate d'Adda 3
Florence 3
Kunming 3
Licata 3
New Delhi 3
Nürnberg 3
Pignone 3
Redmond 3
Taizhou 3
Taranto 3
Washington 3
Afragola 2
Alexandria 2
Altamura 2
Totale 6.753
Salva come PNG Salva come JPEG
Nome #
Remissione, low disease activity e sospensione della terapia immunosoppressiva nel lupus eritematoso sistemico. Risultati dalla coorte prospettica di Padova. 487
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 181
Derivation and validation of the SLE Disease Activity Score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity 167
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 165
Pregnancy and vasculitis: A systematic review of the literature. 162
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 156
Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? 144
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 141
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. 137
Autoinflammation and autoimmunity: Bridging the divide. 134
The kaleidoscope of glucocorticoid effects on immune system 133
Overlap connective tissue disease syndromes. 129
Infections and autoimmunity: the multifaceted relationship. 124
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 124
SERPINB3, apoptosis and autoimmunity 122
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 122
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 119
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis 117
The olfactory function is impaired in patients with idiopathic inflammatory myopathies. 116
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 116
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay 115
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 115
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 115
Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity-a Comprehensive Review. 110
The clinical features, diagnosis and classification of dermatomyositis. 110
New therapeutic strategies in systemic lupus erythematosus management 110
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes 107
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. 105
null 99
Overlap connective tissue disease syndromes. 98
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. 98
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 98
Emerging and critical issues in the pathogenesis of lupus. 97
SLE diagnosis and treatment: When early is early 97
Optimizing outcome in SLE: treating-to-target and definition of treatment goals. 96
Premature coronary heart disease in SLE: can we prevent progression? 95
Crimes against the elderly in Italy, 2007–2014 94
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 93
Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseases 92
Belimumab: a step forward in the treatment of systemic lupus erythematosus 92
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study 88
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 84
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 84
Infection as triggers and complication of sistemic lupus erythematosus 83
Ethical and medico-legal implications of capacity of patients in geriatric surgery 83
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 80
Remission in SLE: The duration depends on multiple factors, including the definition 79
Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. 76
Underage victims and perpetrators of murder in Italy: 2007–2015 76
Women victims of intentional homicide in Italy: New insights comparing Italian trends to German and U.S. trends, 2008–2014 76
Anti-MDA5 dermatomyositis: an update from bench to bedside 75
Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study 75
The body against self: autoinflammation and autoimmunity. 74
Effect of pregnancy on serum cytokines in SLE patients. 73
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 71
Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus. 70
Comment on: Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion: reply 70
Response to: 'SLE-DAS: ready for routine use' by Mathew et al 64
Pentraxins, anti-pentraxins antibodies and atherosclerosis 63
Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan et al 62
Is C-reactive protein an useful tool in monitoring SLE pregnant women? 61
Pregnancy and vasculitis: a systematic review of the literature. 61
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 60
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission 58
Aspetti clinici e immunologici associati agli anitcorpi antisintetasi in una casistica di 42 pazienti 57
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 57
oxLDL/beta 2GPI complex and anti-oxLDL/beta 2GPI in SLE: Prevalence and correlates 56
Preclinical and early systemic lupus erythematosus 56
Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology 56
Expression of regeneration markers in muscle biopsies from patients affected with autoimmune myositis. 55
IgG anti-PTX3 nel lupus eritematoso sistemico 54
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 54
Response to: 'Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population', by Rodríguez-González et al 51
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity 51
NZB/WF1 MICE DEVELOPED ASIA SYNDROME WHEN INJECTED WITH COMPLETE FREUND'S ADJUVANT 50
Response to: 'Remission or low disease activity as a target in systemic lupus erythematosus' by Ugarte-Gilet al 50
Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis 46
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 45
Diagnosi precoce nel LES. 43
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. 42
The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission 40
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 39
Undifferentiated connective tissue disease: State of the art on clinical practice guidelines 36
Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study 31
Il senso dell'olfatto nella poli-dermatomiosite. 31
When to use belimumab in SLE 31
Remissione clinica, terapia e danno cumulativo nel lupus eritematoso sistemico: risultati preliminari su una coorte di 100 pazienti 30
The sense of smell in polimyositis and dermatomyositis. 29
Immunization of NZB/NZWF1 mice with pentraxin 3 delays the onset and reduces the severity of glomerulonephritis. 29
Hormones, immune response, and pregnancy in healthy women and SLE patients 27
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 25
Livelli sierici di BLyS (B lymphocyte stimulator) in pazienti non selezionati affetti da malattie reumatiche autoimmuni 24
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 23
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 23
Prevalence of anti-annexine XI antibodies in patients with autoimmune rheumatic diseases. 23
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study 21
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus 19
Therapeutic Strategies and Outcomes in Neuropsychiatric Systemic Lupus Erythematosus: An International Multicenter Retrospective Study 19
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis 18
Assessment of disease activity and damage in SLE: Are we there yet? 18
Totale 8.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.836
article - articoli 29.425
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.261
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.095 0 0 0 0 0 123 185 186 200 167 162 72
2020/20211.314 78 81 87 108 34 45 47 108 135 244 150 197
2021/20221.206 19 112 146 106 77 80 45 133 63 40 82 303
2022/20231.060 218 120 28 132 136 126 18 64 100 23 48 47
2023/2024883 32 94 93 86 70 96 55 44 65 33 108 107
2024/2025889 29 166 141 124 326 103 0 0 0 0 0 0
Totale 8.344